NCT03562637: Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC |
|
|
| Recruiting | 3 | 668 | Europe, US, RoW | adagloxad simolenin combined with OBI-821, Globo H IHC Assay, Standard of care treatment | OBI Pharma, Inc | Triple Negative Breast Cancer | 12/25 | 12/27 | | |
| Active, not recruiting | 3 | 615 | Europe, Canada, US, RoW | Oregovomab, MAb-B43.13, Paclitaxel, Taxol, Carboplatin, Paraplatin, Placebo | CanariaBio Inc., Gynecologic Oncology Group, Iqvia Pty Ltd | Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms | 09/25 | 08/27 | | |